Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects.
Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health.
A survivorship visit and care plan are mandated for breast cancer survivors by the National Accreditation Program for Breast Centers. These initiatives have improved the quality of follow-up care for cancer survivors and patient satisfaction, but survivorship programs are a work in progress, and some challenges remain as they evolve.
Guided by advances in genomic technology, healthcare has entered the era of precision medicine. With genetic testing now standard of care in oncology practice, cancer is at the forefront of this initiative, but providers still face many concerns.
Childhood cancer therapy can be a double-edged sword: it often leads to a cure, but long after treatment ends, some cancer survivors are still suffering its side effects.
Surviving cancer is the start of a new journey for many individuals. Cancer survivors face a multitude of challenges, including prevention of new and recurrent cancers; interventions for illnesses secondary to cancer and its treatment; concerns related to employment, insurance, and disability; and coordination between specialists and primary care providers.
Survivors of lower gastrointestinal cancers can successfully use Internet-based patient-reported outcomes tools to report late- and long-term effects of their cancer.
As a result of differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts.
With an estimated 15.5 million cancer survivors living in the United States, there is an increased recognition of the need for continuing education of healthcare providers focused on this growing population.
The endocrine therapy landscape has evolved from tamoxifen and aromatase inhibitors to CDK4/6 inhibitors and mTOR inhibitors.
Page 1 of 5
Results 1 - 10 of 47
Results 1 - 10 of 47